BRPI0511768A - composto, pró-droga, métodos para a produção de um composto, e para a profilaxia ou tratamento de cáncer em um mamìfero, agente farmacêutico, e, uso de um composto - Google Patents

composto, pró-droga, métodos para a produção de um composto, e para a profilaxia ou tratamento de cáncer em um mamìfero, agente farmacêutico, e, uso de um composto

Info

Publication number
BRPI0511768A
BRPI0511768A BRPI0511768-2A BRPI0511768A BRPI0511768A BR PI0511768 A BRPI0511768 A BR PI0511768A BR PI0511768 A BRPI0511768 A BR PI0511768A BR PI0511768 A BRPI0511768 A BR PI0511768A
Authority
BR
Brazil
Prior art keywords
compound
optionally substituted
prodrug
prophylaxis
cancer
Prior art date
Application number
BRPI0511768-2A
Other languages
English (en)
Inventor
Tomoyasu Ishikawa
Takahiko Taniguchi
Hiroshi Banno
Masaki Seto
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of BRPI0511768A publication Critical patent/BRPI0511768A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/16—Peri-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Virology (AREA)
  • AIDS & HIV (AREA)
  • Endocrinology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Vascular Medicine (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

COMPOSTO, PRó-DROGA, MéTODOS PARA A PRODUçãO DE UM COMPOSTO, PARA A PROFILAXIA OU TRATAMENTO DE CáNCER EM UM MAMìFERO, AGENTE FARMACêUTICO, E, USO DE UM COMPOSTO A presente invenção diz respeito a um composto representado pela fórmula: em que W é C(R¬ ¹¬) ou N, cada A é um grupo arila opcionalmente substituído ou um grupo heteroarila, X¬ ¹¬ é -NR¬ ³¬-Y~ ¹¬m-, -O-, -S-, -SO-, -SO~ 2~- ou -CHR¬ ³¬- em que R¬ ³¬ é um átomo de hidrogênio ou um grupo hidrocarboneto alifático opcionalmente substituído, ou R¬ ³¬ é opcionalmente ligado a A para formar uma estrutura de anel opcionalmente substituído, R¬ ¹¬ é um átomo de hidrogênio ou um grupo opcionalmente substituído ligado por intermédio de um átomo de carbono, um átomo de nitrogênio ou um átomo de oxigênio, R¬ ²¬ é um átomo de hidrogênio ou grupo opcionalmente substituído ligado por intermédio de um átomo de carbono ou um átomo de enxofre, ou e R¬ ¹¬ e R¬ ²¬, ou R~ ²¬ e R¬ ³¬ são opcionalmente ligados para formar uma estrutura de anel opcionalmente substituído, ou um sal deste e um inibidor da tirosina quinase ou um agente para a profilaxia ou tratamento de câncer, que contenha este composto ou uma pró-droga deste.
BRPI0511768-2A 2004-06-02 2005-06-01 composto, pró-droga, métodos para a produção de um composto, e para a profilaxia ou tratamento de cáncer em um mamìfero, agente farmacêutico, e, uso de um composto BRPI0511768A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2004165050 2004-06-02
JP2005058231 2005-03-02
PCT/JP2005/010451 WO2005118588A1 (ja) 2004-06-02 2005-06-01 縮合複素環化合物

Publications (1)

Publication Number Publication Date
BRPI0511768A true BRPI0511768A (pt) 2008-01-08

Family

ID=35462874

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0511768-2A BRPI0511768A (pt) 2004-06-02 2005-06-01 composto, pró-droga, métodos para a produção de um composto, e para a profilaxia ou tratamento de cáncer em um mamìfero, agente farmacêutico, e, uso de um composto

Country Status (18)

Country Link
US (4) US7507740B2 (pt)
EP (1) EP1752457B1 (pt)
JP (2) JP4134227B2 (pt)
KR (1) KR101194622B1 (pt)
AU (1) AU2005250285B2 (pt)
BR (1) BRPI0511768A (pt)
CA (1) CA2569016C (pt)
CR (1) CR8827A (pt)
GE (1) GEP20105024B (pt)
IL (1) IL179414A (pt)
MA (1) MA28973B1 (pt)
ME (1) MEP8409A (pt)
MX (1) MXPA06013996A (pt)
NO (1) NO20066015L (pt)
NZ (1) NZ551938A (pt)
RU (1) RU2389731C2 (pt)
TW (1) TWI392679B (pt)
WO (1) WO2005118588A1 (pt)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200740820A (en) * 2005-07-05 2007-11-01 Takeda Pharmaceuticals Co Fused heterocyclic derivatives and use thereof
US7932257B2 (en) * 2005-07-22 2011-04-26 Sunesis Pharmaceuticals, Inc. Substituted pyrazolo[4,3-d]pyrimidines as aurora kinase inhibitors
TW200730527A (en) * 2005-12-02 2007-08-16 Takeda Pharmaceuticals Co Fused heterocyclic compound
WO2008033745A2 (en) * 2006-09-11 2008-03-20 Curis, Inc. Fused bicyclic pyrimidines as ptk inhibitors containing a zinc binding moiety
US7517882B2 (en) * 2006-09-18 2009-04-14 Polaris Group Protein kinase inhibitors
EA200970353A1 (ru) * 2006-10-06 2009-10-30 Такеда Фармасьютикал Компани Лимитед Комбинированное лекарственное средство
BRPI0720169A2 (pt) 2006-12-12 2013-12-24 Takeda Pharmaceutical Composto ou um sal do mesmo, prodroga, agente farmacêutico, método para a profilaxia ou tratamento de câncer, e, uso do composto
US7825127B2 (en) * 2006-12-28 2010-11-02 Takeda Pharmaceutical Company, Limited Method for treating cancer
MX2009010517A (es) * 2007-04-05 2009-10-19 Amgen Inc Moduladores de cinasa aurora y metodos de uso.
WO2008145681A2 (en) 2007-05-31 2008-12-04 Boehringer Ingelheim International Gmbh Ccr2 receptor antagonists and uses thereof
JPWO2008156153A1 (ja) 2007-06-19 2010-08-26 武田薬品工業株式会社 癌の予防・治療剤
EP2255830A1 (en) 2008-03-03 2010-12-01 Takeda Pharmaceutical Company Limited Concomitant drug
JPWO2009113560A1 (ja) 2008-03-12 2011-07-21 武田薬品工業株式会社 縮合複素環化合物
JP2011515401A (ja) * 2008-03-20 2011-05-19 アムジエン・インコーポレーテツド オーロラキナーゼモジュレーターおよび使用方法
US9126935B2 (en) 2008-08-14 2015-09-08 Amgen Inc. Aurora kinase modulators and methods of use
WO2010036917A1 (en) * 2008-09-26 2010-04-01 Takeda Pharmaceutical Company Limited Prevention and treatment of cancer with ras gene mutation
WO2010036910A1 (en) * 2008-09-26 2010-04-01 Yoshikazu Ohta Heart protection by administering an amp-activated protein kinase activator
AR073679A1 (es) * 2008-09-26 2010-11-24 Takeda Pharmaceutical Prevencion y tratamiento de cancer con la no expresion de lkb1 supresion o mutacion, composicion farmaceutica. usos
DK2379525T3 (en) 2008-12-19 2015-10-19 Boehringer Ingelheim Int Cyclic pyrimidin-4-carboxamides, as CCR2 receptor antagonists for the treatment of inflammation, asthma and COPD
PE20120593A1 (es) 2009-01-30 2012-05-21 Takeda Pharmaceutical Derivados fusionados de pirimidin-4-ona como antagonistas del receptor de angiotensina ii y como agonistas del receptor ppar gamma
WO2011024871A1 (ja) * 2009-08-26 2011-03-03 武田薬品工業株式会社 縮合複素環誘導体およびその用途
WO2011040212A1 (en) 2009-10-01 2011-04-07 Takeda Pharmaceutical Company Limited Therapeutic agent for brain tumor
WO2011073154A1 (en) 2009-12-17 2011-06-23 Boehringer Ingelheim International Gmbh New ccr2 receptor antagonists and uses thereof
EP2569295B1 (en) 2010-05-12 2014-11-19 Boehringer Ingelheim International GmbH New ccr2 receptor antagonists, method for producing the same, and use thereof as medicaments
US8877745B2 (en) 2010-05-12 2014-11-04 Boehringer Ingelheim International Gmbh CCR2 receptor antagonists, method for producing the same, and use thereof as medicaments
US8841313B2 (en) 2010-05-17 2014-09-23 Boehringer Ingelheim International Gmbh CCR2 antagonists and uses thereof
US9018212B2 (en) 2010-05-25 2015-04-28 Boehringer Ingelheim International Gmbh Pyridazine carboxamides as CCR2 receptor antagonists
EP2576538B1 (en) 2010-06-01 2015-10-28 Boehringer Ingelheim International GmbH New CCR2 antagonists
CA2760174A1 (en) * 2011-12-01 2013-06-01 Pharmascience Inc. Protein kinase inhibitors and uses thereof
AU2012244550C1 (en) * 2011-04-21 2017-06-22 Origenis Gmbh Pyrazolo [4, 3-d] pyrimidines useful as kinase inhibitors
JP5786258B2 (ja) 2011-07-15 2015-09-30 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規かつ選択的なｃｃｒ２拮抗薬
GB201311888D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201311891D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compound
MX367085B (es) * 2013-07-31 2019-08-05 Merck Patent Gmbh Piridinas, pirimidinas y pirazinas como inhibidores de tirosina cinasa de bruton e inhibidores y usos de las mismas.
WO2015134539A1 (en) * 2014-03-03 2015-09-11 The Regents Of The University Of California Mcl-1 antagonists
US20180228907A1 (en) 2014-04-14 2018-08-16 Arvinas, Inc. Cereblon ligands and bifunctional compounds comprising the same
WO2015162515A1 (en) 2014-04-25 2015-10-29 Pfizer Inc. Heteroaromatic compounds and their use as dopamine d1 ligands
SG11201608299TA (en) 2014-05-01 2016-11-29 Novartis Ag Compounds and compositions as toll-like receptor 7 agonists
KR102139847B1 (ko) 2014-05-01 2020-07-31 노파르티스 아게 톨-유사 수용체 7 효능제로서의 화합물 및 조성물
WO2017004537A1 (en) 2015-07-02 2017-01-05 Centrexion Therapeutics Corporation (4-((3r,4r)-3-methoxytetrahydro-pyran-4-ylamino)piperidin-1-yl)(5-methyl-6-(((2r,6s)-6-(p-tolyl)tetrahydro-2h-pyran-2-yl)methylamino)pyrimidin-4yl)methanone citrate
SG11201802769RA (en) 2015-10-29 2018-05-30 Novartis Ag Antibody conjugates comprising toll-like receptor agonist
EP3591845B1 (en) * 2018-07-05 2023-08-09 Universite De Bretagne Sud Sorting device and method for elementary check node processing for message-passing decoding of non-binary codes
WO2020118183A1 (en) * 2018-12-06 2020-06-11 Kapoor Tarun M 2,4-diaminopyrimidine bicycles for treating cancer

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS554116B2 (pt) * 1971-08-20 1980-01-29
ES2103131T3 (es) * 1993-06-21 1997-08-16 Merrell Pharma Inc Nuevos agentes de nucleosido carbociclico utiles como inhibidores selectivos de citoquinas proinflamatorias.
IL112248A0 (en) 1994-01-25 1995-03-30 Warner Lambert Co Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
IL112249A (en) 1994-01-25 2001-11-25 Warner Lambert Co Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
EP0831829B1 (en) * 1995-06-07 2003-08-20 Pfizer Inc. Heterocyclic ring-fused pyrimidine derivatives
US6395733B1 (en) 1995-06-07 2002-05-28 Pfizer Inc Heterocyclic ring-fused pyrimidine derivatives
EP0836605B1 (en) 1995-07-06 2002-02-06 Novartis AG Pyrrolopyrimidines and processes for the preparation thereof
AR004010A1 (es) 1995-10-11 1998-09-30 Glaxo Group Ltd Compuestos heterociclicos
JP3370340B2 (ja) * 1996-04-12 2003-01-27 ワーナー―ランバート・コンパニー チロシンキナーゼの不可逆的阻害剤
EA199900021A1 (ru) 1996-07-13 1999-08-26 Глаксо, Груп Лимитед Бициклические гетероароматические соединения в качестве ингибиторов протеинтирозинкиназы
AU720429B2 (en) * 1996-08-23 2000-06-01 Novartis Ag Substituted pyrrolopyrimidines and processes for their preparation
JPH10130258A (ja) 1996-10-10 1998-05-19 Eli Lilly & Co ベンゾ［ｂ］チオフェン化合物、中間体、製剤、および方法
CA2272705C (en) * 1996-11-27 2003-03-18 Pfizer Inc. Fused bicyclic pyrimidine derivatives
IL133430A0 (en) 1997-08-05 2001-04-30 Pfizer Prod Inc 4-AMINOPYRROLE (3, 2-d) PYRIMIDINES AS NEUROPEPTIDE Y RECEPTOR ANTAGONISTS
US6187777B1 (en) * 1998-02-06 2001-02-13 Amgen Inc. Compounds and methods which modulate feeding behavior and related diseases
WO2000005234A1 (en) * 1998-07-22 2000-02-03 Suntory Limited NF-λB INHIBITORS CONTAINING INDAN DERIVATIVES AS THE ACTIVE INGREDIENT
CZ27399A3 (cs) * 1999-01-26 2000-08-16 Ústav Experimentální Botaniky Av Čr Substituované dusíkaté heterocyklické deriváty, způsob jejich přípravy, tyto deriváty pro použití jako léčiva, farmaceutická kompozice a kombinovaný farmaceutický přípravek tyto deriváty obsahující a použití těchto derivátů pro výrobu léčiv
JP3270834B2 (ja) 1999-01-27 2002-04-02 ファイザー・プロダクツ・インク 抗がん剤として有用なヘテロ芳香族二環式誘導体
UA71945C2 (en) 1999-01-27 2005-01-17 Pfizer Prod Inc Substituted bicyclic derivatives being used as anticancer agents
AU7323000A (en) * 1999-08-26 2001-04-10 Plant Research International B.V. Conditional inhibition of vegetative propagation
RU2003134646A (ru) 2001-04-30 2005-04-20 Глэксо Груп Лимитед (GB) Конденсированные пиримидины в качестве антагонистов кортикотропинвысокобождающего фактора (crf)
WO2002088095A1 (en) 2001-04-30 2002-11-07 Glaxo Group Limited Fused pyrimidines as antagonists of the corticotropin releasing factor (crf)
GB0119249D0 (en) 2001-08-07 2001-10-03 Novartis Ag Organic compounds
US8507445B2 (en) 2001-09-07 2013-08-13 Board Of Regents, The University Of Texas System Compositions and methods of use of targeting peptides for diagnosis and therapy of human cancer
JP2003183283A (ja) * 2001-12-18 2003-07-03 Takeda Chem Ind Ltd 縮合インドール化合物、その製造法および用途
ATE478872T1 (de) 2002-03-28 2010-09-15 Ustav Ex Botan Av Cr V V I I O Pyrazoloä4,3-düpyrimidine, verfahren zu ihrer herstellung und therapeutische anwendung
US7531553B2 (en) * 2003-03-21 2009-05-12 Amgen Inc. Heterocyclic compounds and methods of use
US7268133B2 (en) * 2003-04-23 2007-09-11 Pfizer, Inc. Patent Department Cannabinoid receptor ligands and uses thereof
MXPA05012839A (es) 2003-05-27 2006-05-17 Pfizer Prod Inc Quinazolinas y pirido[3,4-d] pirimidinas como inhibidores de receptores tirosina quinasa.
US7572799B2 (en) 2003-11-24 2009-08-11 Pfizer Inc Pyrazolo[4,3-d]pyrimidines as Phosphodiesterase Inhibitors
JP2006020985A (ja) 2004-07-05 2006-01-26 Kiyoshi Owada 微小孔を用いた入浴剤用炭酸ガス拡散装置
CA2573538C (en) * 2004-07-30 2014-11-25 Methylgene Inc. Inhibitors of vegf receptor and hgf receptor signaling
ES2473341T3 (es) * 2005-05-20 2014-07-04 Methylgene Inc Inhibidores de la se�alizaci�n del receptor del VEGF y del receptor del HGF
TW200730527A (en) * 2005-12-02 2007-08-16 Takeda Pharmaceuticals Co Fused heterocyclic compound
EA200970353A1 (ru) * 2006-10-06 2009-10-30 Такеда Фармасьютикал Компани Лимитед Комбинированное лекарственное средство
JPWO2008156153A1 (ja) * 2007-06-19 2010-08-26 武田薬品工業株式会社 癌の予防・治療剤
JPWO2009113560A1 (ja) * 2008-03-12 2011-07-21 武田薬品工業株式会社 縮合複素環化合物

Also Published As

Publication number Publication date
CA2569016A1 (en) 2005-12-15
RU2006147267A (ru) 2008-07-20
US7507740B2 (en) 2009-03-24
AU2005250285A1 (en) 2005-12-15
JPWO2005118588A1 (ja) 2008-04-03
JP4937172B2 (ja) 2012-05-23
CR8827A (es) 2007-04-20
IL179414A (en) 2013-11-28
MA28973B1 (fr) 2007-11-01
EP1752457A4 (en) 2010-05-26
EP1752457A1 (en) 2007-02-14
TW200611907A (en) 2006-04-16
EP1752457B1 (en) 2014-03-19
NZ551938A (en) 2010-07-30
AU2005250285B2 (en) 2011-08-18
RU2389731C2 (ru) 2010-05-20
NO20066015L (no) 2007-02-13
JP4134227B2 (ja) 2008-08-20
TWI392679B (zh) 2013-04-11
US20090029973A1 (en) 2009-01-29
US20070244132A1 (en) 2007-10-18
MXPA06013996A (es) 2007-02-08
US20090018335A1 (en) 2009-01-15
KR101194622B1 (ko) 2012-10-29
IL179414A0 (en) 2007-05-15
GEP20105024B (en) 2010-06-25
CA2569016C (en) 2012-11-27
US20090203717A1 (en) 2009-08-13
US8178543B2 (en) 2012-05-15
WO2005118588A1 (ja) 2005-12-15
MEP8409A (en) 2011-12-20
JP2008247907A (ja) 2008-10-16
KR20070026695A (ko) 2007-03-08

Similar Documents

Publication Publication Date Title
ECSP10010356A (es) Derivados de carboxamidas n-azabicíclicas, su preparación y su aplicación en terapéutica
TW200611907A (en) Fused heterocyclic compound
JO2644B1 (en) Derivatives of N- (amino-aryl mixture) -H1- indole-2-carboxamide Synthesis and therapeutic use
BRPI0407283A (pt) Composto, composição farmacêutica, e, agente ativador de glucoquinase, agentes terapêuticos e/ou agentes preventivos para diabetes melito e obesidade
BRPI0510305A (pt) composto ou um sal do mesmo, pródroga ou um sal da mesma, agente farmacêutico, método de produção do composto ou um sal do mesmo, inibidor de metaloproteinase de matriz ou um sal do mesmo ou uma pródroga do mesmo, método de inibir uma metaloproteinase de matriz, e, uso de um composto ou de um sal do mesmo ou de uma pródroga do mesmo
BR122019003178B1 (pt) método de controle de pestes
BRPI0514644A (pt) composto fosforamidita, composto ácido ribonucléico, e método para produzir oligo-rna
CR10072A (es) Derivados de pirimidinil-aril-urea que son inhibidores de fgf
MY149512A (en) Pyrazolylaminopyridine derivatives useful as kinase inhibitors
BRPI0412347A (pt) 2-aminofenil-4-fenilpiridinas como inibidores de quinase
CY1110900T1 (el) Χημικες ενωσεις
CY1108275T1 (el) Χημικες ενωσεις
DE60206911D1 (de) Imidazol-2-carbonsäureamid derivate als raf-kinase-inhibitoren
BRPI0720993B8 (pt) usos de compostos análogos de ciclopamina
MX2007015863A (es) Inhibidores de esfingosina cinasa.
UY29886A1 (es) Derivados de pirazol novedosos, composiciones farmaccuticas que los contienen, procedimientos para la preparacinn de los mismos y aplicaciones
CY1109681T1 (el) Υποκατεστημενα παραγωγα κιναζολινης ως αναστολεις των κινασων aurora
BRPI0412894A (pt) tienopiridina e furopiridina inibidores de quinases
BRPI0408353A (pt) composto, composição farmacêutica, métodos para o tratamento de neoplasias suscetìveis e para o tratamento de infecções virais, e, uso de um composto
BRPI0718966B8 (pt) composto, composição farmacêutica, inibidor plk1 e agente antitumoral
BR112012007411A2 (pt) composto, processo para sua preparação e composição farmacêutica contendo o mesmo
ECSP088084A (es) Derivados de n-(heteroaril)-1-heteroarilalquil-1h-indol-2-carboxamidas, su preparación y su aplicación en terapéutica
UA99485C2 (ru) Хиназолиндионовые производные, их получение и их применение в терапии
SE0403171D0 (sv) New compounds
BRPI0406721A (pt) Compostos condensados de furano

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 10A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2310 DE 14-04-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.